| Balance sheet (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 7.56M | 6.07M | 9.29M | 13.52M | 15.19M | 11.67M |
| Total current assets | 13.43M | 16.04M | 20.90M | 41.74M | 62.69M | 11.84M |
| Property, plant and equipment | 176.0K | 250.0K | 303.0K | 367.0K | 357.0K | 152.0K |
| Total assets | 13.81M | 16.96M | 22.15M | 43.06M | 64.35M | 12.48M |
| Total current liabilities | 1.48M | 3.22M | 4.84M | 6.75M | 2.65M | 1.32M |
| Total liabilities | 1.48M | 3.43M | 5.15M | 6.84M | 2.89M | 1.67M |
| Retained earnings | -111.62M | -102.62M | -88.68M | -63.82M | -36.17M | -23.70M |
| Shareholders' equity | 12.33M | 13.54M | 17.00M | 36.22M | 61.47M | 10.80M |
From Chemomab Therapeutics Ltd.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.